Applying intensified design of experiments to mammalian cell culture processes.

best‐cost strategy early stage development industrial mammalian cell culture intensified design of experiments modeling upstream bioprocessing

Journal

Engineering in life sciences
ISSN: 1618-0240
Titre abrégé: Eng Life Sci
Pays: Germany
ID NLM: 101193313

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 17 09 2021
revised: 17 09 2021
accepted: 18 10 2021
entrez: 14 12 2022
pubmed: 15 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

The analysis of data collected using design of experiments (DoE) is the current gold standard to determine the influence of input parameters and their interactions on process performance and product quality. In early development, knowledge on the bioprocess of a new product is limited. Many input parameters need to be investigated for a thorough investigation. For eukaryotic cell cultures, intensified DoE (iDoE) has been proposed as efficient tool, requiring fewer bioreactor runs by introducing setpoint changes during the bioprocess. We report the first successful application of iDoE to mammalian cell culture, performing sequential setpoint changes in the growth phase for the selected input parameters temperature and dissolved oxygen. The process performance data were analyzed using ordinary least squares regression. Our results indicate iDoE to be applicable to mammalian bioprocesses and to be a cost-efficient option to inform modeling early on during process development. Even though only half the number of bioreactor runs were used in comparison to a classical DoE approach, the resulting models revealed comparable input-output relations. Being able to examine several setpoint levels within one bioreactor run, we confirm iDoE to be a promising tool to speed up biopharmaceutical process development.

Identifiants

pubmed: 36514527
doi: 10.1002/elsc.202100123
pii: ELSC1455
pmc: PMC9731596
doi:

Types de publication

Journal Article

Langues

eng

Pagination

784-795

Informations de copyright

© 2021 The Authors. Engineering in Life Sciences published by Wiley‐VCH GmbH.

Déclaration de conflit d'intérêts

Raphael Drerup, Ingo Gorr, Lisa Junghans, Bettina Knapp, Verena Nold, Beate Presser, Thomas Schwab and Stefan Wieschalka have been employees of Boehringer Ingelheim during this study. Lorenzo Bisgen declares no conflict of interest.

Références

Microb Cell Fact. 2015 Jan 08;14:1
pubmed: 25567661
Biotechnol Prog. 2015 Jul-Aug;31(4):1119-27
pubmed: 25967555
Eng Life Sci. 2016 Oct 14;17(11):1173-1184
pubmed: 32624745
Biotechnol Prog. 2016 Sep;32(5):1343-1352
pubmed: 27126552
J Biotechnol. 2016 Feb 10;219:98-109
pubmed: 26707809
Trends Biotechnol. 2020 Oct;38(10):1141-1153
pubmed: 32518043
MAbs. 2020 Jan-Dec;12(1):1754999
pubmed: 32449439
Biotechnol J. 2020 Sep;15(9):e2000121
pubmed: 32501577
Biotechnol Bioeng. 2009 Dec 15;104(6):1107-20
pubmed: 19623562
Biotechnol Prog. 2015 Sep-Oct;31(5):1163-71
pubmed: 26013818
Biotechnol J. 2017 Jul;12(7):
pubmed: 28371494
Bioprocess Biosyst Eng. 2019 May;42(5):867-882
pubmed: 30806781
Biotechnol Bioeng. 2000 Aug 5;69(3):242-55
pubmed: 10861404
MAbs. 2009 Sep-Oct;1(5):443-52
pubmed: 20065641
Drug Dev Ind Pharm. 2017 Jun;43(6):889-901
pubmed: 28166428
Nat Biotechnol. 2018 Dec 6;36(12):1136-1145
pubmed: 30520869
PLoS One. 2015 Oct 19;10(10):e0140597
pubmed: 26480023
J Biotechnol. 2001 Jul 12;88(3):259-68
pubmed: 11434971

Auteurs

Verena Nold (V)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Lisa Junghans (L)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Lorenzo Bisgen (L)

University of Ulm Ulm Germany.

Raphael Drerup (R)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Beate Presser (B)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Ingo Gorr (I)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Thomas Schwab (T)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Bettina Knapp (B)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Stefan Wieschalka (S)

Development Biologicals Boehringer Ingelheim Pharma GmbH & Co KG Biberach an der Riß Germany.

Classifications MeSH